Angiotensin receptor-mediated oxidative stress is associated with impaired cardiac redox signaling and mitochondrial function in insulin-resistant rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 4, 2013, Pages

  Vázquez Medina, José Pablo ^a   Popovich, Irina ^a   Thorwald, Max A ^a   Viscarra, Jose A ^a   Rodriguez, Ruben ^a   Sonanez Organis, Jose G ^a   Lam, Lisa ^b   Peti Peterdi, Janos ^b   Nakano, Daisuke ^c   Nishiyama, Akira ^c   Ortiz, Rudy M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

Metabolic syndrome; NADPH oxidase; Nrf2

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ANGIOTENSIN 1 RECEPTOR; CATALASE; CITRATE SYNTHASE; GLUTATHIONE PEROXIDASE; OLMESARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUCCINATE DEHYDROGENASE; SUCCINIC ACID; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CELL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID OXIDATION; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

METABOLIC SYNDROME; NADPH OXIDASE; NRF2;

ALDEHYDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CATALASE; CITRATE (SI)-SYNTHASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE PEROXIDASE; IMIDAZOLES; INSULIN RESISTANCE; MALE; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA, HEART; MYOCARDIUM; NADPH OXIDASE; NF-E2-RELATED FACTOR 2; OBESITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, INBRED OLETF; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; TETRAZOLES; TIME FACTORS; TYROSINE;

EID: 84881619152     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00101.2013     Document Type: Article

References (65)

1. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 106: 1253-1264, 2010.
2. Ago T, Matsushima S, Kuroda J, Zablocki D, Kitazono T, Sadoshima J. The NADPH oxidase Nox4 and aging in the heart. Aging (Milano) 2: 1012-1016, 2010.
3. Anilkumar N, Weber R, Zhang M, Brewer A, Shah AM. Nox4 and Nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arterioscler Thromb Vasc Biol 28: 1347-1354, 2008.
4. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med 38: 1278-1295, 2005.
5. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002.
6. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, Stas S, Kumar P, Sha Q, Ferrario CM, Sowers JR. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 288: E353-E359, 2005.
7. Block K, Gorin Y, Abboud HE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci USA 106: 14385-14390, 2009.
8. 2-induced endothelial dysfunction. Free Radic Biol Med 41: 810-817, 2006.
9. Brewer AC, Murray TVA, Arno M, Zhang M, Anilkumar NP, Mann GE, Shah AM. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 51: 205-215, 2011.
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005.
11. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802-805, 2003.
12. Choi H, Leto TL, Hunyady L, Catt KJ, Bae YS, Rhee SG. Mechanism of angiotensin II-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J Biol Chem 283: 255-267, 2008.
13. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907, 2005.
14. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintrón M, Chen T, Marcinek DJ, Dorn GW, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Gαq overexpression-induced heart failure. Circ Res 108: 837-846, 2011.
15. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
16. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 51: 1289-1301, 2011.
17. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt H, Harrison DG, Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45: 1340-1351, 2008.
18. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 102: 488-496, 2008.
19. Fernandez-Campo L, Grande M, Diego J, Fuentes-Calvo I, Macias-Nunez J, Sánchez-Rodríguez A, Grande J, García-Ortiz L, Lopez-Novoa J, Martinez-Salgado C. Effect of different antihypertensive treatments on Ras, MAPK and Akt activation in hypertension and diabetes. Clin Sci 116: 165-173, 2009.
20. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 317: 350-357, 1987.
21. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82: 9-20, 2009.
22. Helmcke I, Heumüller S, Tikkanen R, Schröder K, Brandes RP. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid Redox Signal 11: 1279-1287, 2009.
23. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese zucker rats. Hypertension 38: 884-890, 2001.
24. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36: 1199-1207, 2004.
25. Kakehi T, Yabe-Nishimura C. NOX enzymes and diabetic complications. Semin Immunopathol 30: 301-314, 2008.
26. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24: S317-S320, 1994.
27. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41: 1422, 1992.
28. Kim KS, Abraham D, Williams B, Violin JD, Mao L, Rockman HA. β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303: H1001-H1010, 2012.
29. Kong X, Zhang D, Wu H, Li F. Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats. Biol Pharm Bull 34: 693-699, 2011.
30. Kosugi R, Shioi T, Watanabe-Maeda K, Yoshida Y, Takahashi K, Machida Y, Izumi T. Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. Circ J 70: 482, 2006.
31. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511-515, 2002.
32. Li J, Stouffs M, Serrander L, Banfi B, Bettiol E, Charnay Y, Steger K, Krause KH, Jaconi ME. The NADPH oxidase NOX4 drives cardiac differentiation: role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell 17: 3978-3988, 2006.
33. Li P, Koike T, Jiang H, Wang Z, Kawata Y, Oshida Y. Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats. Horm Metab Res 44: 286-290, 2012.
34. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51: 319-325, 2008.
35. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
37. Montez P, Vázquez-Medina JP, Rodríguez R, Thorwald MA, Viscarra JA, Lam L, Peti-Peterdi J, Nakano D, Nishiyama A, Ortiz RM. Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats. Endocrinology 153: 5746-5759, 2012.
38. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35: 851-859, 2003.
39. Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD. Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain. Biochemistry 49: 2433-2442, 2010.
40. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin IIinduced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
41. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42: 206-212, 2003.
42. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368-1376, 2011.
43. Reaven GM. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
44. Rodriguez R, Viscarra JA, Minas JN, Nakano D, Nishiyama A, Ortiz RM. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology 53: 1684-1695, 2012.
45. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 Is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217-1225, 2012.
46. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114, 2007.
47. Shen GX. Mitochondrial dysfunction, oxidative stress and diabetic cardiovascular disorders. Cardiovasc Hematol Disord Drug Targets 12: 106-112, 2012.
48. Shen GX. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can J Physiol Pharmacol 88: 241-248, 2010.
49. Sirker A, Zhang M, Murdoch C, Shah AM. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol 27: 649-660, 2007.
50. Sirker A, Zhang M, Shah A. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 106: 735-747, 2011.
51. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, Hedrick CC. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 47: 1727-1734, 2004.
52. 2+ release channel by NADPH oxidase 4. Proc Natl Acad Sci USA 108: 16098-16103, 2011.
53. Takac I, Schröder K, Zhang L, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, Brandes RP. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 286: 13304-13313, 2011.
54. Toma I, Kang JJ, Sipos A, Vargas S, Bansal E, Hanner F, Meer E, Peti-Peterdi J. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 118: 2526-2534, 2008.
55. Vázquez-Medina JP, Crocker DE, Forman HJ, Ortiz RM. Prolonged fasting does not increase oxidative damage or inflammation in postweaned northern elephant seal pups. J Exp Biol 213: 2524-2530, 2010.
56. von Löhneysen K, Noack D, Hayes P, Friedman JS, Knaus UG. Constitutive NADPH oxidase 4 activity resides in the composition of the B-loop and the penultimate C terminus. J Biol Chem 287: 8737-8745, 2012.
57. Wang Z, Koike T, Li P, Jiang H, Natsume Y, Mu L, Chen T, Oshida Y. Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet. Life Sci 90: 322-327, 2012.
58. Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JMD, Müller J, Schuhmacher S, Hortmann M, Baldus S, Gori T. First evidence for a crosstalk between mitochondrial and NADPH oxidasederived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal 10: 1435-1448, 2008.
59. Wosniak J Jr, Santos CXC, Kowaltowski AJ, Laurindo FRM. Crosstalk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal 11: 1265-1278, 2009.
60. Yamamoto E, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Lai ZF, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S. Pravastatin enhances beneficial effects of olmesartan on vascular injury of saltsensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 27: 556-563, 2007.
61. Zhang L, Nguyen MVC, Lardy B, Jesaitis AJ, Grichine A, Rousset F, Talbot M, Paclet MH, Qian G, Morel F. New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4. Biochimie 93: 457-468, 2011.
62. Zhang M, Brewer AC, Schröder K, Santos CXC, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 107: 18121-18126, 2010.
63. Zhang M, Perino A, Ghigo A, Hirsch E, Shah A. NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal 18: 1024-1041, 2013.
64. 2. Hypertension 46: 732-737, 2005.
65. Zhou MS, Schulman IH, Raij L. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol 296: H833-H839, 2009.